Presentation TCT 2016 TCT 263: Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents Presenter: Kevin J. Beatt, Frederick Feit October 31, 2016
Presentation TCT 2016 TCT 261: Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-Eluting and Birolimus-Eluting Stents with Biodegradable Polymer. From the SORT OUT VII Trial Presenter: Kevin J. Beatt, Frederick Feit October 31, 2016
Presentation TCT 2016 TCT 67: Impact of the SYNTAX Score in Patients With Diabetes and Left-Main and/or Multivessel Coronary Disease: A Pooled Analysis of Individual Patient Level Data From the SYNTAX, PRECOMBAT and BEST Trials Presenter: Sorin J. Brener, Jean-François Tanguay, Rafael Cavalcante October 31, 2016
Presentation TCT 2016 TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials Presenter: Sorin J. Brener, Jean-François Tanguay, Jaya Chandrasekhar October 31, 2016
Presentation TCT 2016 TCT 66: Effects of Dual Antiplatelet Therapy Cessation Among Patients With Diabetes Mellitus After PCI With DES Presenter: Sorin J. Brener, Jean-François Tanguay, Michela Faggioni October 31, 2016
Presentation TCT 2016 Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management? Presenter: Felix Mahfoud, Michael A. Weber, Ehtisham Mahmud October 30, 2016
Presentation TCT 2016 Personalized Medicine Where Are We in 2016? Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy October 30, 2016
Presentation TCT 2016 Anti-inflammatory Therapies for Atherosclerosis Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif October 30, 2016
Presentation TCT 2016 Heart Failure Advances (Ivabradine, ARNI, and More) Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy October 30, 2016
Presentation TCT 2016 Diabetes Advances (SGLT-2, GLP-1, DPP4) Presenter: Robert A. Harrington, A. Michael Lincoff, Norman E. Lepor October 30, 2016
Presentation TCT 2016 Reversal of Chronic Anticoagulation: When, What, and How Effective? Presenter: Paul A. Gurbel, James A. Reiffel October 30, 2016
Presentation TCT 2016 Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents Presenter: Paul A. Gurbel, Christopher B. Granger October 30, 2016
Presentation TCT 2016 Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents Presenter: David J. Moliterno October 30, 2016
Presentation TCT 2016 Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents Presenter: Paul A. Gurbel, Harvey D. White October 30, 2016
Presentation TCT 2016 PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia) Presenter: Sorin J. Brener, Franz-Josef Neumann, Sunil V. Rao October 30, 2016
Presentation TCT 2016 Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx October 30, 2016
Presentation TCT 2016 Pharmacotherapy for Hybrid PCI/CABG Cases Presenter: Sorin J. Brener, Franz-Josef Neumann, Laura Mauri October 30, 2016
Presentation TCT 2016 Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.) Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber October 30, 2016
Presentation TCT 2016 ACS Case Presentation: Where Pharmacotherapy Failed Presenter: C. Michael Gibson, Daniel I. Simon, Gennaro Giustino October 30, 2016
Presentation TCT 2016 Limitations of Pharmacotherapy Clinical Trial Design Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul October 30, 2016